Trademark: 79345734
Word
C CENYX BIOTECH
Status
Registered
Status Code
700
Status Date
Tuesday, March 26, 2024
Serial Number
79345734
Registration Number
7333762
Registration Date
Tuesday, March 26, 2024
Mark Type
5
Filing Date
Friday, April 29, 2022
Published for Opposition
Tuesday, January 9, 2024

Trademark Owner History
Cenyx Biotech Inc. - Original Registrant

Classifications
5 Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; veterinary preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for animal and poultry; radio-isotope markers for therapeutic or diagnostic use; in vitro diagnostic preparations for medical purposes; vaccines; contrast media for use in medical imaging equipment; contrast media for in vivo imaging; drug delivery agents in the form of compounds, wrapping wafers, edible wafers that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention of inflammatory disorders; non-prescription medicines, namely, medicinal preparations in the nature of pills, tablets, capsules, caplets, liquid drops, sachets, oral liquids, suspensions, liquids, semi-solids, creams, syrups, ointments, lotions, gels, sprays, emulations, oils, pessaries, suppositories, granules and films for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; radioactive pharmaceutical preparations for use in vivo diagnostics or therapeutic use; diagnostic agents for medical purposes; biological preparations for medical purposes, namely, biological preparations for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes for medical or veterinary purposes; pharmaceuticals for the treatment of infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioural disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, congenital malformations, deformations and chromosomal abnormalities, or injury, poisoning and certain other consequences of external causes; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of cardiovascular disease; drug delivery agents in the form of tablets or capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of inflammatory diseases; antibodies for medical purposes
42 Scientific research in the nature of conducting clinical trials for others in the field of cardiovascular disease; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of medicine; analysis, and evaluation of medical product development services of others to assure compliance with industry standards; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy
The mark consists of the following: a stylized letter "C" in the colors purple, green, blue-green, and teal. The wording "CENYX" appears in navy blue stylized font, and further below is the wording "BIOTECH" in blue-green stylized font.
The color purple, blue-green, teal, emerald and navy are harmonized in C-shaped letter. The color navy appears in the word CENYX and the color blue-green appears in the word BIOTECH.
The color(s) purple, blue-green, teal, green, and navy blue is/are claimed as a feature of the mark.
"BIOTECH"

Trademark Events
Jul 22, 2022
New Application Office Supplied Data Entered
Jul 21, 2022
Sn Assigned For Sect 66a Appl From Ib
Jul 26, 2022
Application Filing Receipt Mailed
Feb 17, 2023
Assigned To Examiner
Mar 8, 2023
Non-Final Action Written
Mar 9, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Apr 27, 2023
Refusal Processed By Mpu
Apr 27, 2023
Non-Final Action Mailed - Refusal Sent To Ib
May 17, 2023
Refusal Processed By Ib
Oct 24, 2023
Teas Response To Office Action Received
Oct 24, 2023
Correspondence Received In Law Office
Oct 24, 2023
Teas/Email Correspondence Entered
Nov 5, 2023
Assigned To Examiner
Nov 7, 2023
Assigned To Examiner
Nov 29, 2023
Examiners Amendment -Written
Nov 29, 2023
Examiners Amendment E-Mailed
Nov 29, 2023
Notification Of Examiners Amendment E-Mailed
Nov 29, 2023
Examiner's Amendment Entered
Nov 29, 2023
Approved For Pub - Principal Register
Dec 20, 2023
Notification Of Possible Opposition Sent To Ib
Dec 20, 2023
Notification Of Notice Of Publication E-Mailed
Dec 20, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Dec 27, 2023
Notification Of Possible Opposition Sent To Ib
Jan 8, 2024
Notification Processed By Ib
Jan 9, 2024
Published For Opposition
Jan 9, 2024
Official Gazette Publication Confirmation E-Mailed
Mar 26, 2024
Registered-Principal Register
Mar 26, 2024
Notice Of Registration Confirmation Emailed
Jun 27, 2024
Final Disposition Notice Created, To Be Sent To Ib
Jan 13, 2024
Notification Of Possible Opposition - Processed By Ib
Dec 27, 2023
Notification Of Possible Opposition Created, To Be Sent To Ib

Trademark Alertz updated from USPTO on 2030-01-24